GRTS Gritstone Oncology Inc.

6.65
+0.55  (+9%)
Previous Close 6.1
Open 6.29
Price To Book 1.83
Market Cap 245,892,741
Shares 36,976,352
Volume 137,927
Short Ratio
Av. Daily Volume 145,979
Stock charts supplied by TradingView

NewsSee all news

  1. Gritstone Oncology Announces the Appointment of Veteran Legal Executive Rahsaan Thompson as General Counsel

    EMERYVILLE, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  2. Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  3. Gritstone Oncology to Present at Two Investor Conferences in March

    EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  4. Gritstone Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference

    EMERYVILLE, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  5. Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress

    EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 efficacy data due mid-2020.
GRANITE-001 (GO-004)
Solid tumors
Phase 1 efficacy data due mid-2020.
SLATE-001
Solid tumors

Latest News

  1. Gritstone Oncology Announces the Appointment of Veteran Legal Executive Rahsaan Thompson as General Counsel

    EMERYVILLE, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  2. Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  3. Gritstone Oncology to Present at Two Investor Conferences in March

    EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  4. Gritstone Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference

    EMERYVILLE, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  5. Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress

    EMERYVILLE, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  6. Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference

    EMERYVILLE, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  7. Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  8. Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy

    -Poster Presentation at SITC 2019 Annual Meeting- EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of

  9. Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference

    EMERYVILLE, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  10. Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within "Off-The-Shelf" SLATE Immunotherapy at SITC 2019 Annual Meeting

    EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer

  11. Gritstone Oncology to Present at Cantor Global Healthcare Conference

    EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types,

  12. Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones

    EMERYVILLE, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer